CEO Albert Bourla Reflects on Pfizer’s Year of Bold Moves and Relentless Innovation in 2025 Annual Review

2025 was a typically busy year for Pfizer, one of strong performance, disciplined execution and bold moves that position us for future growth and lasting impact for patients around the world as we continue to pursue our mission of making breakthroughs that change people’s lives.

The entire organization remained focused on addressing the world’s most pressing health challenges, and 2025 was a year of significant progress toward that goal. We’ve detailed some of the highlights in our latest Annual Review.

This year’s report puts Pfizer under the microscope and showcases how we:

• Invested in R&D to drive progress in oncology, vaccines, immunology, and more
• Made strides in obesity and oncology toward addressing unmet patient needs
• Prioritized strategic partnerships to deliver our medicines and vaccines to patients worldwide 

At Pfizer, progress is measured not only by performance, but by the impact we make for patients. Throughout the year, Pfizer continued advancing medicines and vaccines that address some of the world’s most significant health challenges. A diverse global portfolio helped reach hundreds of millions of patients, underscoring the company’s commitment to expanding access and improving health outcomes across regions. This work reflects ongoing progress against Pfizer’s long-term ambitions and the belief that innovation must translate into real world impact for patients and communities. 

Efforts to strengthen differentiated scientific leadership remained central to progress. Pfizer continued strengthening its research and development capabilities, including expanding the use of artificial intelligence and emerging technologies to help accelerate the discovery, development, and delivery of new medicines and vaccines.

As always, our Annual Review opens with perspective from CEO Albert Bourla, who shares about the great strides Pfizer made over the course of 2025, and how that positions the company to make further leaps in the second half of the decade.

“Our focus was clear: Guided by our purpose, we advanced science, accelerated innovation and helped patients gain access to the medicines and vaccines they needed.

We’re striving to increase the speed of everything we do to drive high-quality innovation to improve lives. 2025 was a year of progress, with improved productivity and margins made possible, in part, by simplifying and streamlining our business.”

Read the rest of Albert’s message, and explore more about Pfizer’s performance, priorities, and progress over the past year, in the full 2025 Annual Review: https://annualreview.pfizer.com/